The Senores Pharmaceuticals Limited IPO presents an intriguing opportunity for investors, with a book-built issue valued at ₹582.11 crores. The offering consists of a fresh issue of 1.28 crore shares, raising ₹500 crores, aimed at funding the company’s growth and operational requirements. Additionally, there is an offer for sale (OFS) of 0.21 crore shares, amounting to ₹82.11 crores, allowing existing shareholders to partially exit their investment. This IPO provides a mix of growth capital and liquidity for stakeholders, making it a noteworthy event for market participants keen on exploring new investment opportunities.
The IPO is open for subscription from December 20, 2024, to December 24, 2024, offering investors a limited window to participate in this opportunity. The price band is set between ₹372 and ₹391 per share, providing flexibility for bidders within this range. Investors can apply in multiples of the lot size of 38 shares, making the minimum investment more accessible. With its structured bidding process and competitive pricing, this IPO is set to attract attention from retail and institutional investors alike.
Senores Pharmaceuticals IPO Details
| IPO Date | December 20, 2024 to December 24, 2024 | ||
| Listing Date | 30 December, 2024 | ||
| Face value | ₹10 per share | ||
| Price band | ₹372 to ₹391 per share | ||
| Lot size | 38 Shares | ||
| Total Issue Size | 1,48,87,723 shares (aggregating up to ₹582.11 Cr) | ||
| Fresh Issue | 1,27,87,723 shares (aggregating up to ₹ 500.00 Cr) | ||
| Offer for Sale | 21,00,000 shares of ₹10 (aggregating up to ₹82.11 Cr) | ||
| Issue Type | Book Built Issue IPO | ||
| Listing At | BSE, NSE |
Senores Pharmaceuticals IPO Lot Size calculator
| Application | Lots | Share | Amount |
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| BS-HNI | 68 | 2,584 | ₹10,10,344 |
Senores Pharmaceuticals IPO Distribution
| Investor Category | Shares Offered | Maximum Allottees |
| Anchor Investor Shares Offered | 66,65,725 (45%) | N/A |
| QIB Shares Offered | 44,43,817 (30%) | N/A |
| NII (HNI) Shares Offered | 22,21,909 (15%) | |
| bNII > ₹10L | 15,18,605 (10.25%) | 2,854 |
| sNII < ₹10L | 7,03,304 (4.75%) | 1,322 |
| Retail Shares Offered | 14,81,272 (10%) | 38,980 |
| Total Shares Offered | 1,48,12,723 (100%) |
About Senores Pharmaceuticals Limited Company
Senores Pharmaceuticals Limited, incorporated in December 2017, is a global leader in the manufacturing of high-quality pharmaceutical products. With operations spanning across the United States, Canada, the United Kingdom, and other emerging markets, the company is committed to improving global healthcare. Senores Pharmaceuticals offers a diverse product portfolio, including essential medications such as Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, and Butalbital, Acetaminophen, and Caffeine Capsules. The company also produces life-saving drugs like Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, and Nicardipine Hydrochloride Capsules, along with a wide array of other products like Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, and Terazosin Capsules USP. In addition, Senores Pharmaceuticals manufactures Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, and many other important medications, including Irbesartan Tablets, Risperidone Tablets, Topiramate Capsules, and Ivermectin Tablets. These products cater to regulated markets, ensuring compliance with stringent quality standards. Furthermore, the company has expanded its footprint into 43 emerging markets, where it continues to provide accessible and affordable pharmaceutical solutions to a wide range of patients, furthering its mission to enhance healthcare outcomes globally.
Senores Pharmaceuticals Limited Company Finances
Amount in ₹ Crore
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit after tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Net Worth | 319.06 | 231.71 | 45.05 | 36.59 |
Leave a Reply